Cromoglicic acid

Cromoglicic acid

Clinical data
AHFS/Drugs.com	International Drug Names
License data	US FDA: Cromolyn
Pregnancy category	AU: B1
Routes of administration	topical: oral, nasal spray, inhaled, eye drops
ATC code	A07EB01 (WHO) D11AH03 (WHO) R01AC01 (WHO) R03BC01 (WHO) S01GX01 (WHO)
Legal status
Legal status	AU: S2 (Pharmacy medicine) UK: inhaler POM; eye OTC US: OTC nasal; eye, inhaler: Rx only
Pharmacokinetic data
Bioavailability	1%
Elimination half-life	1.3 hours
Identifiers
IUPAC name 5,5′-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-carboxylic acid)
CAS Number	16110-51-3 Y
PubChem CID	2882
IUPHAR/BPS	7608
DrugBank	DB01003 N
ChemSpider	2779 Y
UNII	Y0TK0FS77W
KEGG	D07753 Y
ChEBI	CHEBI:59773 Y
ChEMBL	ChEMBL74 N
CompTox Dashboard (EPA)	DTXSID4022860
ECHA InfoCard	100.036.602
Chemical and physical data
Formula	C23H16O11
Molar mass	468.370 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C=4Oc3cccc(OCC(O)COc2cccc1O/C(=C\C(=O)c12)C(=O)O)c3C(=O)C=4
InChI InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30) Y Key:IMZMKUWMOSJXDT-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.

It is considered a breakthrough drug in management of asthma, as the patients can be freed from steroids in many cases; however, it is mainly effective as a prophylaxis for allergic and exercise-induced asthma, not as a treatment for acute asthma attacks.^{[citation needed]}

Cromoglicic acid has been the non-corticosteroid treatment of choice in the treatment of asthma, for which it has largely been replaced by leukotriene receptor antagonists because of their safety and convenience. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.^[1]